Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

EQRx, Inc. (EQRX)

3.46   -0.32 (-8.47%) 12-05 16:00
Open: 3.78 Pre. Close: 3.78
High: 3.79 Low: 3.4
Volume: 2,089,906 Market Cap: 1,690(M)

Technical analysis

as of: 2022-12-06 8:17:46 AM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 5.47     One year: 6.66
Support: Support1: 3.03    Support2: 2.52
Resistance: Resistance1: 4.68    Resistance2: 5.7
Pivot: 3.51
Moving Average: MA(5): 3.6     MA(20): 3.83
MA(100): 4.81     MA(250): 4.79
MACD: MACD(12,26): -0.4     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 53.1     %D(3): 41.1
RSI: RSI(14): 38.4
52-week: High: 9.96  Low: 2.63
Average Vol(K): 3-Month: 2,954 (K)  10-Days: 1,792 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ EQRX ] has closed above bottom band by 40.7%. Bollinger Bands are 61.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.8 - 3.81 3.81 - 3.83
Low: 3.36 - 3.38 3.38 - 3.39
Close: 3.43 - 3.46 3.46 - 3.49

Company Description

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Headline News

Fri, 02 Dec 2022
EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer - GlobeNewswire

Mon, 28 Nov 2022
Nearly a year after his SPAC combines with EQRx, Eli Casdin resigns from board - Endpoints News

Wed, 23 Nov 2022
EQRx Inc (EQRX) Stock Increases 4.07% This Week; Should You Buy? - InvestorsObserver

Mon, 21 Nov 2022
EQRx backtracks on plans to reduce pricing of lead cancer treatments -

Sun, 13 Nov 2022
EQRx, Inc. (EQRX) Q3 2022 Earnings Call Transcript - Seeking Alpha

Fri, 11 Nov 2022
EQRX stock extends post-earnings slump as Goldman Sachs, Jefferies downgrade (NASDAQ:EQRX) - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 488 (M)
Shares Float 216 (M)
% Held by Insiders 25.2 (%)
% Held by Institutions 65.7 (%)
Shares Short 21,190 (K)
Shares Short P.Month 23,780 (K)

Stock Financials

EPS -0.15
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.94
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -21.6
Return on Equity (ttm) -15.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.72
Qtrly Earnings Growth 0
Operating Cash Flow -262 (M)
Levered Free Cash Flow -140 (M)

Stock Valuations

PE Ratio -23.7
PEG Ratio 0
Price to Book value 1.17
Price to Sales 0
Price to Cash Flow -6.46

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.